MRNA News and Press, Moderna Inc.

2024-07-02 11:49:49 ET More on Moderna, Pfizer, etc. Pfizer: It Could Be A Bargain Moderna: Really Strong Competition Novavax seeks FDA authorization for updated JN.1 COVID shot Wall Street Lunch: Pfizer Looks To Take Next Step In Weight-Loss Drugs ...

2024-07-02 10:37:11 ET Summary Eaton Vance Risk-Managed Diversified Equity Income Fund offers high current income with equity exposure for income-minded investors. Inflation might be higher than official numbers suggest, making equities a good hedge; the fund's 8.90% yield compare...

2024-07-02 10:12:01 ET Summary The First Trust Nasdaq-100-Technology Sector Index Fund ETF focuses on technology stocks from the Nasdaq 100 index with an equal-weight strategy. Despite underperforming the Nasdaq 100 index in the past, QTEC has the potential to outperform in the se...

2024-07-02 07:48:18 ET More on Moderna Moderna: Really Strong Competition Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Alnylam, Lilly, AstraZeneca among best perf...

CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...

2024-06-30 20:30:56 ET Rounding out the top five were Moderna ( NASDAQ: MRNA ) and Novo Nordisk ( NVO ) with gains of, respectively, ~12.5% and ~11.9% .... Read the full article on Seeking Alpha For further details see: Alnylam, Lilly, AstraZeneca among best ...

2024-06-30 05:15:50 ET Summary Moderna's success with COVID-19 vaccine approval under Operation Warp Speed led to a temporary revenue surge, but future sales may be limited due to politicization of vaccines and competition. Moderna's vaccine pipeline faces intense competition from...

2024-06-29 15:44:55 ET More on Eli Lilly, Novo Nordisk, etc. Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End ...

2024-06-29 11:35:00 ET The Health Care Select Sector SPDR Fund ETF ( NYSEARCA: XLV ), tracking the healthcare companies under S&P 500, rose 0.11% in the second quarter of 2024, lagging behind the broader S&P 500 index which rose 4.30%.... Read the full article on Seeki...

2024-06-28 09:14:26 ET More on Carisma Therapeutics Carisma to cut 37% of workforce, stock falls 8% Seeking Alpha’s Quant Rating on Carisma Therapeutics Historical earnings data for Carisma Therapeutics Financial information for Carisma Therapeutics ...